Free Trial

Cellectar Biosciences (CLRB) Competitors

Cellectar Biosciences logo
$4.80 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$4.78 -0.02 (-0.42%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLRB vs. CUE, KLRS, RENB, VRCA, HOWL, BLUE, IPA, IPSC, RNXT, and AADI

Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Cue Biopharma (CUE), Kalaris Therapeutics (KLRS), Renovaro (RENB), Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), bluebird bio (BLUE), ImmunoPrecise Antibodies (IPA), Century Therapeutics (IPSC), RenovoRx (RNXT), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

Cellectar Biosciences vs. Its Competitors

Cellectar Biosciences (NASDAQ:CLRB) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by insiders. Comparatively, 12.3% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cellectar Biosciences has a net margin of 0.00% compared to Cue Biopharma's net margin of -507.87%. Cue Biopharma's return on equity of -228.43% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -619.70% -158.04%
Cue Biopharma -507.87%-228.43%-114.66%

Cue Biopharma has higher revenue and earnings than Cellectar Biosciences. Cue Biopharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$44.58M-$21.92-0.22
Cue Biopharma$9.29M5.68-$40.67M-$0.67-1.05

Cellectar Biosciences presently has a consensus price target of $375.00, indicating a potential upside of 7,712.50%. Cue Biopharma has a consensus price target of $3.00, indicating a potential upside of 328.45%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Cue Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Cue Biopharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cellectar Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

In the previous week, Cellectar Biosciences had 9 more articles in the media than Cue Biopharma. MarketBeat recorded 13 mentions for Cellectar Biosciences and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.61 beat Cellectar Biosciences' score of 0.52 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cellectar Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cue Biopharma
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cue Biopharma beats Cellectar Biosciences on 11 of the 14 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLRB vs. The Competition

MetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$8.69M$10.35B$5.45B$8.93B
Dividend YieldN/A2.07%5.22%4.01%
P/E Ratio-0.2216.9127.2420.06
Price / SalesN/A29.29426.15116.88
Price / CashN/A23.9726.2128.59
Price / Book0.533.637.925.55
Net Income-$44.58M$235.43M$3.17B$248.56M
7 Day Performance-32.49%0.02%4.40%7.56%
1 Month Performance-55.65%-0.33%2.64%8.54%
1 Year Performance-93.31%-10.79%35.04%21.80%

Cellectar Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLRB
Cellectar Biosciences
3.2919 of 5 stars
$4.80
flat
$375.00
+7,712.5%
-93.3%$8.69MN/A-0.2210Gap Down
CUE
Cue Biopharma
4.0618 of 5 stars
$0.68
-7.9%
$3.00
+339.7%
-28.3%$51.41M$9.29M-1.0260
KLRS
Kalaris Therapeutics
N/A$2.67
+1.9%
N/AN/A$49.93MN/A0.00110Positive News
Gap Up
RENB
Renovaro
1.129 of 5 stars
$0.29
-1.3%
N/A-82.6%$49.73MN/A-0.3820
VRCA
Verrica Pharmaceuticals
3.6153 of 5 stars
$0.53
+1.4%
$8.00
+1,409.1%
-91.0%$49.03M$7.57M-0.4440
HOWL
Werewolf Therapeutics
3.0417 of 5 stars
$1.09
+6.9%
$8.33
+664.5%
-48.0%$48.91M$1.88M-0.6540Positive News
BLUE
bluebird bio
2.0882 of 5 stars
$4.97
flat
$44.60
+797.4%
N/A$48.67M$103.95M-0.13520
IPA
ImmunoPrecise Antibodies
2.5085 of 5 stars
$1.06
-4.5%
$4.00
+277.4%
+33.5%$48.51M$18.16M-0.9180News Coverage
Gap Up
IPSC
Century Therapeutics
2.0324 of 5 stars
$0.56
+7.7%
$4.20
+651.7%
-75.0%$48.14M$6.59M-1.93170High Trading Volume
RNXT
RenovoRx
2.861 of 5 stars
$1.32
+2.7%
$7.25
+451.3%
+18.9%$48.09M$40K-3.296Positive News
AADI
Aadi Bioscience
0.6423 of 5 stars
$1.93
+1.6%
$1.67
-13.6%
+49.6%$47.67M$25.07M-0.8540

Related Companies and Tools


This page (NASDAQ:CLRB) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners